# Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Study · id `cardio:ct-nct05225077` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05225077](<https://clinicaltrials.gov/study/NCT05225077>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05225077

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

## Technical summary

Registry record NCT05225077. Randomized; no masking; primary purpose prevention. Start 2022-01-01 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT05225077, source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT05225077, source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT05225077, source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05225077, source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05225077, source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05225077-2022-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
- Condition: Renal Insufficiency, Chronic
- Condition: Cardiac Catheterization
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Dapagliflozin 10 MG \[Farxiga\]
- Lead sponsor: Dong-A University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (Farxiga) (`cardio:farxiga`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Dong-A University (`cardio:org-dong-a-university`)

## Provenance

Content hash: c4368d065bd8bfd09f847fbdebb6d0278bd78a7da26611a656e6329a51990852
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
